Twenty-Four–hour Duration of Effect of Intranasal Corticosteroids for Seasonal Allergic Rhinitis Symptoms: Clinical Evidence and Relevance

Abstract

Background

Seasonal allergic rhinitis (SAR) symptoms are often most severe and/or disruptive during overnight and morning hours, resulting in cognitive/performance impairments and reduced quality of life throughout the following day. Surveys of allergy patients and health care practitioners reveal a common perception that intranasal steroids (INSs), many of which are dosed q.d., fail to adequately relieve symptoms for a full 24 hours. This review assessed whether perceptions of the 24-hour duration of action of INSs correspond with duration of action documented in clinical literature.

Methods

SAR clinical trial literature of the last 5 years was reviewed to identify studies of INSs incorporating morning instantaneous (A.M. NOW) or instantaneous assessments of 24-hour duration of action.

Results

In numerous placebo-controlled trials of INSs in patients with SAR, treatment was associated with significantly greater improvements in A.M. NOW symptoms from baseline versus placebo. For congestion, this is noteworthy, because patients often cite this symptom, especially in the morning, as the most bothersome symptom. Comparison of A.M. NOW and daily scores suggests minimal drop in efficacy at 24 hours postdose. In several studies, INS treatment was found superior to intranasal or oral antihistamines in A.M. NOW symptom improvement.

Conclusion

Once-daily INSs have potential for effective 24-hour symptom relief; however, there is an apparent disconnect between these findings and patient/physician perceptions. This discrepancy may be explained, in part, by less-than-ideal treatment adherence among “real-world” patients versus subjects treated in clinical trials. Proactive counseling can encourage proper INS use and help maximize treatment benefits.

Get full access to this article

View all access options for this article.

References

Nathan

Meltzer

Derebery

, . The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 29:600–608, 2008.

Bousquet

Khaltaev

Cruz

, . Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen). Allergy 63(suppl 86):8–160, 2008.

Blaiss

MS.

Allergic rhinitis: Direct and indirect costs.

Allergy Asthma Proc 31:375–380, 2010.

Malone

Lawson

Smith

, . A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 99:22–27, 1997.

Long

AA.

Findings from a 1000-patient internet-based survey assessing the impact of morning symptoms on individuals with allergic rhinitis.

Clin Ther 29:342–351, 2007.

Naclerio

Hadley

Stoloff

, . Patient and physician perspectives on the attributes of nasal allergy medications. Allergy Asthma Proc 28(suppl 1):S11–S17, 2007.

van Cauwenberge

Bachert

Passalacqua

, . Consensus statement on the treatment of allergic rhinitis. Allergy 55:116–134, 2000.

Dykewicz

and Fineman

(Eds). Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology.

Ann Allergy Asthma Immunol 81:478–518, 1998.

Brozek

Bousquet

Baena-Cagnani

, . Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol 126:466–476, 2010.

10.

Scadding

Durham

Mirakian

, . BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 38:19–42, 2008.

11.

Weiner

Abramson

and Puy

RM.

Intranasal corticosteroids versus oral H₁ receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials.

BMJ 317:1624–1629, 1998.

12.

Yanez

and Rodrigo

GJ.

Intranasal corticosteroids versus topical H₁ receptor antagonists for the treatment of allergic rhinitis: A systematic review with meta-analysis.

Ann Allergy Asthma Immunol 89: 479–484, 2002.

13.

Hampel

Ratner

Van Bavel

, . Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 105:168–173, 2010.

14.

Di Lorenzo

Pacor

Pellitteri

, . Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in monotherapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 34:259–267, 2004.

15.

Anolik

and Mometasone Furoate Nasal Spray With Loratadine Study Group. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100:264–271, 2008.

16.

Benninger

Farrar

Blaiss

, . Evaluating approved medications to treat allergic rhinitis in the United States: An evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 104:13–29, 2010.

17.

AstraZeneca

LP.

Rhinocort Aqua prescribing information. Revised 12/2010. Wilmington, DE; 2004.

18.

Altana Pharma US Inc. Omnaris prescribing information. Revised 10/2011. Florham Park, NJ; 2009.

19.

GlaxoSmithKline. Veramyst prescribing information. Revised 10/2011. Research Triangle Park, NC; 2009.

20.

GlaxoSmithKline. Flonase prescribing information. Revised 8/2007. Research Triangle Park, NC; 2004.

21.

Schering Corp. (now Merck & Co.). Nasonex prescribing information. Revised 1/2011. Kenilworth, NJ; 2009.

22.

sanofi-aventis U.S., LLC. Nasacort prescribing information. Revised 11/2010. Bridgewater, NJ; 2006.

23.

Andrews

Martin

Jacobs

, . Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc 30:128–138, 2009.

24.

Jacobs

Martin

Hampel

, . Effectiveness of fluticasone furoate 100 μg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr Med Res Opin 25:1393–1401, 2009.

25.

Nathan

Berger

Yang

, . Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 100: 497–505, 2008.

26.

Fokkens

Jogi

Reinartz

, . Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 62:1078–1084, 2007.

27.

Kaiser

Naclerio

Given

, . Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 119:1430–1437, 2007.

28.

Martin

Ratner

Hampel

, . Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 28:216–225, 2007.

29.

Meltzer

Shekar

and Teper

AA.

Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis.

Allergy Asthma Proc 32:159–167, 2011.

30.

Bernstein

van Bavel

Shekar

, . Once-daily mometasone furoate nasal spray provides effective 24-hour relief of nasal congestion in subjects with moderate-to-severe seasonal allergic rhinitis. J Allergy Clin Immunol 125(Suppl 2): Abstract 177, 2010.

31.

LaForce

CF.

Duration of action of mometasone furoate nasal spray in seasonal allergic rhinitis: A double-blind, placebo-controlled study.

Ann Allergy Asthma Immunol 100(Suppl 1): Abstract 90, 2008.

32.

Prenner

Lanier

Bernstein

, . Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 125:1247–1253.e5, 2010.

33.

Dykewicz

Spector

Shekar

, . Once-daily mometasone furoate nasal spray provides relief of nasal symptoms of seasonal allergic rhinitis 24 hrs after dosing. Ann Allergy Asthma Immunol 107(Suppl 1): Abstract 119, 2010.

34.

Varghese

Patel

, . Duration of action of mometasone furoate nasal spray in subjects with symptoms of seasonal allergic rhinitis induced in an environmental exposure chamber. J Allergy Clin Immunol 122:S54, 2008.

35.

Ratner

Wingertzahn

van Bavel

, . Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 97:657–663, 2006.

36.

Salapatek

Patel

Gopalan

, . Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am J Rhinol Allergy 24:1–6, 2010.

37.

Zieglmayer

Bareille

, . Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Cur Med Res Opin 24:1833–1840, 2008.

38.

Craig

McCann

Gurevich

, . The correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol 114: S139–S145, 2004.

39.

Young

Finn

and Kim

; University of Wisconsin Sleep and Respiratory Research Group. Nasal obstruction as a risk factor for sleep-disordered breathing. J Allergy Clin Immunol 99:S757–S762, 1997.

40.

Meltzer

Munafo

Chung

, . Intranasal mometasone furoate therapy for allergic rhinitis symptoms and rhinitis-disturbed sleep. Ann Allergy Asthma Immunol 105:65–74, 2010.

41.

Lanier

Meltzer

Gates

, . Onset and duration of action of concomitant administration of mometasone furoate nasal spray with oxymetazoline nasal spray versus either drug alone and placebo in subjects with seasonal allergic rhinitis. J Allergy Clin Immunol 125(Suppl 1): Abstract 173, 2010.

42.

Rodrigo

and Neffen

Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: A systematic review.

Clin Exp Allergy 41:160–170, 2011.

43.

Kaliner

Storms

Tilles

, . Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 μg in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc 30:255–262, 2009.

44.

Shedden

Impact of nasal congestion on quality of life and work productivity in allergic rhinitis.

Treat Respir Med 4:439–446, 2005.

45.

White

Smith

Baker

, . Symptom control in patients with hay fever in UK general practice: How well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy 28:266–270, 1997.